How much should Medicare pay for drugs?

被引:26
作者
Newhouse, JP [1 ]
机构
[1] Harvard Univ, Cambridge, MA 02138 USA
关键词
D O I
10.1377/hlthaff.23.1.89
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Discussions of the Medicare drug benefit have focused more on what beneficiaries will pay than what pharmaceutical manufacturers will receive. A key choice is the degree to which Medicare must become involved in setting manufacturers' prices. If prices must be set, Medicare could do so using average wholesale price, comparison with prices in other markets, cost, or rate-of-return regulation. Because all four methods have substantial drawbacks, Medicare should not initially attempt to set prices, but to prevent abuses in pricing, Congress should allow cost to be considered in coverage decisions.
引用
收藏
页码:89 / 102
页数:14
相关论文
共 37 条
[1]  
ABELSON R, 2003, NY TIMES 0126
[2]  
AVERCH H, 1962, AM ECON REV, V52, P1052
[3]  
BERNDT ER, 2000, J HLTH EC MAY, P373
[4]  
*C BUDG OFF, 2002, ISS DES PRESCR DRUG
[5]  
*CBO, 1996, MED REB PRESCR DRUG
[6]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[7]  
Dorfman R, 1954, AM ECON REV, V44, P826
[8]   Why medicare cannot promulgate a national coverage rule:: A case of regula mortis [J].
Foote, SB .
JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2002, 27 (05) :707-730
[9]   Prescription drug prices: Why do some pay more than others do? [J].
Frank, RG .
HEALTH AFFAIRS, 2001, 20 (02) :115-128
[10]  
FRANK RG, 2003, J HLTH EC MAR, P325